Ziemelkurzemes regionala slimnica SIA

The medical center is at the forefront of research in Thyroid Eye Disease (TED), focusing on innovative treatments to improve patient outcomes. The center's work in this area is characterized by its exploration of novel therapeutic agents, such as batoclimab, which is being assessed for its efficacy in maintaining and improving eye health in TED patients.

• Batoclimab Efficacy in TED
• Proptosis Management
• Long-term Treatment Strategies

Through rigorous clinical trials, the center is contributing to the understanding of how to effectively manage and treat TED, offering hope for improved quality of life for those affected by this condition.

In the field of Wet Age-related Macular Degeneration (wAMD), the medical center is pioneering research into biosimilar treatments that promise to enhance therapeutic options for patients. The center's studies compare the efficacy and safety of new biosimilar candidates against established treatments, such as Lucentis, aiming to provide more accessible and cost-effective solutions.

• Biosimilar Development
• Comparative Efficacy Studies
• Patient Safety and Outcomes

By advancing research in biosimilars, the center is playing a crucial role in expanding treatment possibilities for wAMD, potentially reducing the burden of this vision-impairing disease.